NEJM Quick Take video summary of The Recircuit Trial
The RE-CIRCUIT Trial (Calkins et al., 2017) was investigated the safety and efficacy of uninterrupted dabigatran vs uninterrupted warfarin in patients undergoing ablation of atrial fibrillation). The results from the trial demonstrated a lower incidence of major bleeding events with dabigatran than warfarin and no differences in the incidence of stroke or systemic embolism were observed.
Video

Dabigatran was associated with fewer bleeding complications compared to uninterrupted warfarin